Rofecoxib's COX-2 Selectivity Mechanism
Rofecoxib, marketed as Vioxx, is a selective COX-2 inhibitor that targets the cyclooxygenase-2 (COX-2) enzyme over COX-1 by exploiting structural differences in their active sites. COX enzymes catalyze arachidonic acid conversion to prostaglandins, with COX-1 maintaining housekeeping functions like gastric protection and COX-2 driving inflammation.[1]
The COX-2 active site has a larger secondary pocket due to a Val523 residue (Ile523 in COX-1), which is accessible only in COX-2. Rofecoxib's sulfonamide group extends into this pocket, forming stabilizing hydrogen bonds with Arg513 and His90, while its central butanone ring occupies the main channel.[1][2]
Key Structural Interactions
- Main channel binding: Rofecoxib's heterocyclic furanone ring mimics arachidonic acid, binding near Tyr385 and Ser530, essential for catalysis in both enzymes.
- Selective pocket access: The molecule's C4-side chain (methylsulfone) fits the COX-2 Val523 cavity, causing steric clash with COX-1's bulkier Ile523, reducing COX-1 binding by over 250-fold (IC50 ratio).[2][3]
- Hydrogen bonding: The sulfonamide NH donates a bond to Phe381's carbonyl; the SO2 accepts from Arg120, locking it in COX-2.[1]
This yields >1000-fold selectivity, minimizing COX-1 inhibition linked to gastrointestinal risks.[3]
How It Compares to Nonselective NSAIDs
Unlike ibuprofen, which binds both COX-1 and COX-2 similarly via the main channel without pocket exploitation, rofecoxib avoids COX-1's steric hindrance. Aspirin acetylates Ser530 irreversibly in both, lacking selectivity.[2]
| Drug | COX-2 IC50 (nM) | COX-1 IC50 (nM) | Selectivity (COX-2/COX-1) |
|------|-----------------|-----------------|---------------------------|
| Rofecoxib | 8 | >15,000 | >1,875x [3] |
| Celecoxib | 30 | 18,000 | 600x [3] |
| Ibuprofen | 3,400 | 80 | 0.02x [2] |
Why COX-1 Selectivity Matters for Side Effects
COX-1 inhibition causes ulcers by reducing mucosal prostaglandins; rofecoxib's profile cut GI events vs. naproxen in trials (4.5% vs. 11.9%). However, COX-2 selectivity linked it to cardiovascular risks via thromboxane/prostacyclin imbalance.[1][4]
Crystal Structure Evidence
X-ray structures (PDB: 3PGH for COX-2:rofecoxib) confirm the sulfonamide deep in the Arg-His pocket, absent in COX-1 models due to Ile occlusion.[1][2]
Sources
[1]: Nature Reviews Drug Discovery - COX-2 inhibitors
[2]: PNAS - Structural basis for COX-2 selectivity
[3]: J Med Chem - Rofecoxib selectivity data
[4]: NEJM - APPROVe trial CV risks